High incidence of cetuximab-related infusion reactions in head and neck cancer pts (real life data) V. Palomar, M. Annereau, N. Lezghed, C. Even, L. Mayache-Badis, M. Iacob, C. Leibu, M. Matias, P. Bravo and C. Ferte Institut Gustave Roussy, Villejuif, France Background: Cetuximab is crucial in the management of squamous cell carcinoma of the head and neck (SCCHN) patients. Grade 3-4 infusion reactions (IRs) occur in 2% of colorectal cancer (ASPECCT study, ?1000 pts).